Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 72 articles:
HTML format



Single Articles


    July 2022
  1. HUNYADY P, Herrmann E, Bojunga J, Friedrich-Rust M, et al
    Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury.
    Eur J Gastroenterol Hepatol. 2022;34:801-806.
    PubMed     Abstract available


  2. PARIENTE A, Rosa I, Dharancy S, Hanslik B, et al
    Nonalcoholic fatty liver disease: opinions, population served, and management from a sample of French hepato(gastroentero)logists (PERSEPT study).
    Eur J Gastroenterol Hepatol. 2022;34:791-800.
    PubMed     Abstract available


    May 2022
  3. SUN J, Yu X, Weng Z, Jin L, et al
    The impact of hepatotoxic drugs on the outcome of patients with acute deterioration of hepatitis B virus-related chronic disease.
    Eur J Gastroenterol Hepatol. 2022 May 5. pii: 00042737-990000000-00024.
    PubMed     Abstract available


  4. DOFFOEL M, Tripon S, Ernwein F, Chaffraix F, et al
    Changes in the profile and therapeutic care of people who use drugs with HCV mono-infection: a retrospective study between 2015 and 2019 from a monocentric tertiary referent center in France.
    Eur J Gastroenterol Hepatol. 2022;34:560-566.
    PubMed     Abstract available


    April 2022
  5. ALLGEIER J, Weber S, Todorova R, Neumann J, et al
    Acute liver injury following methylprednisolone pulse therapy: 13 cases from a prospectively collected cohort.
    Eur J Gastroenterol Hepatol. 2022;34:457-461.
    PubMed     Abstract available


    March 2022
  6. TAHTASAKAL CA, Oncul A, Sevgi DY, Demirbas D, et al
    Fibrosis scores that can be used in follow-up of after direct-acting antiviral treatment: APRI, FIB-4, King score and GUCI.
    Eur J Gastroenterol Hepatol. 2022;34:308-315.
    PubMed     Abstract available


    February 2022
  7. TOYODA H, Yasuda S, Shiota S, Kumada T, et al
    Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97088.
    PubMed     Abstract available


  8. HUANG X, Wang H, Zhang W, Gu E, et al
    Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97084.
    PubMed     Abstract available


    December 2021
  9. DOFFOEL M, Ernwein F, Chaffraix F, Haumesser L, et al
    Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants.
    Eur J Gastroenterol Hepatol. 2021 Dec 30. pii: 00042737-900000000-97102.
    PubMed     Abstract available


  10. NG A
    Underdiagnosis of hepatitis C in the community: do not forget vulnerable populations.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  11. NG A
    Hepatocellular carcinoma recurrence after directly-acting antiviral therapy: caution with hepatitis C.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  12. BASSO M, Zago D, Pozzetto I, Parisi SG, et al
    Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  13. KUMADA T, Toyoda H, Yasuda S, Ito T, et al
    Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  14. HUBBARD A, Hirode G, Chitnis A, Wong R, et al
    Prevalence of hepatitis B surface antigen and hepatitis B core antibody among adults with latent tuberculosis infection.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


    September 2021
  15. EL KASSAS M, Abdeen N, Omran D, Alboraie M, et al
    Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 Sep 21. pii: 00042737-900000000-97142.
    PubMed     Abstract available


  16. PATACCINI G, Pedrozo W, Mathet VL, Biglione MM, et al
    Prevalence of hepatitis D virus in blood donors with different hepatitis B virus markers of infection.
    Eur J Gastroenterol Hepatol. 2021;33:1229.
    PubMed    


  17. PI B, Wang J, Tong Y, Yang Q, et al
    Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.
    Eur J Gastroenterol Hepatol. 2021 Sep 1. pii: 00042737-900000000-97150.
    PubMed     Abstract available


    July 2021
  18. ALEM SA, Eletreby R, Abdellatif Z, Ramadan A, et al
    Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jul 6. pii: 00042737-900000000-97183.
    PubMed     Abstract available


  19. EL RAY A, Fouad R, ElMakhzangy H, El Beshlawy M, et al
    Characterizing a cohort of Egyptian patients with acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2021;33:1023-1028.
    PubMed     Abstract available


    June 2021
  20. LIU X, Zhang J, Wei X, Duan Z, et al
    HBV-related acute-on-chronic liver failure with underlying chronic hepatitis has superior survival compared to cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 Jun 29. pii: 00042737-900000000-97185.
    PubMed     Abstract available


  21. KHAN A, Sami K, Malik A, Mujtaba Bhinder M, et al
    Clinical outcomes and healthcare utilization of acute hepatitis A virus infection with acute kidney injury in hospitalized patients.
    Eur J Gastroenterol Hepatol. 2021 Jun 17. pii: 00042737-900000000-97190.
    PubMed     Abstract available


    May 2021
  22. KOSEKLI MA
    Mean platelet volume and platelet to lymphocyte count ratio are associated with hepatitis B-related liver fibrosis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97205.
    PubMed     Abstract available


  23. SHI K, Li P, Xue D, Liu Y, et al
    Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97202.
    PubMed     Abstract available


    April 2021
  24. HAYES KN, Burkard T, Weiler S, Tadrous M, et al
    Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
    Eur J Gastroenterol Hepatol. 2021 Apr 21. pii: 00042737-900000000-97232.
    PubMed     Abstract available


  25. EKMEN N, Can G, Can H
    Preliminary examination of the relations between disease stage, illness perceptions, coping strategies, and psychological morbidity in chronic hepatitis B and C guided by the Common-Sense Model of Illness.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97249.
    PubMed     Abstract available


  26. YEO YH, Kam LY, Le MH, Jeong D, et al
    A population-based US study of hepatitis C diagnosis rate.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97245.
    PubMed     Abstract available


  27. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication.
    Eur J Gastroenterol Hepatol. 2021 Apr 9. pii: 00042737-900000000-97256.
    PubMed     Abstract available


  28. OZNUR M, Topcu B, Celikkol A
    Predictive value of noninvasive indices in chronic hepatitis B virus-related fibrosis.
    Eur J Gastroenterol Hepatol. 2021;33:577-582.
    PubMed     Abstract available


    March 2021
  29. SERWAH MA, Omar SA, Khedr MS, Abdel-Hamid AES, et al
    Occurrence and clinical characteristics of occult hepatitis C virus infection in hemodialysis units at Ismailia, Egypt.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97270.
    PubMed     Abstract available


    February 2021
  30. SAHIN M, Sucu P, Serin E, Yetim A, et al
    Serum fibrosis markers could aid in the prediction of factor for successful oral antiviral treatment in hepatitis C.
    Eur J Gastroenterol Hepatol. 2021 Feb 5. pii: 00042737-900000000-97302.
    PubMed     Abstract available


  31. SAUD LRC, Chagas AL, Maccali C, Pinto PVA, et al
    Hepatocellular carcinoma in patients coinfected with hepatitis B or C and HIV: more aggressive tumor behavior?
    Eur J Gastroenterol Hepatol. 2021 Feb 5. pii: 00042737-900000000-97300.
    PubMed     Abstract available


    January 2021
  32. VIJAYALEKSHMI B, Sharma A, Prabhu SB, Nair SC, et al
    Reticuloendothelial activation correlates with disease severity and predicts mortality in severe alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97323.
    PubMed     Abstract available


  33. EL-NAHAAS SM, Rady NH, Malek S, Serag K, et al
    Changes in serum interferon-gamma-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97309.
    PubMed     Abstract available


  34. EL KASSAS M, Alboraie M, El-Sayed M, Elbehiry S, et al
    Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jan 14. doi: 10.1097/MEG.0000000000002043.
    PubMed     Abstract available


  35. YILMAZ B, Kayadibi H, Yeniova AO, Koseoglu H, et al
    The age, bilirubin and albumin (ABA) index: a novel noninvasive index for predicting liver fibrosis in patients with chronic hepatitis C infection.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


  36. PESTANA NF, Equi CMA, Gomes CP, Cardoso AC, et al
    Aminotransferase-to-platelet ratio index and Fibrosis-4 index score predict hepatic fibrosis evaluated by transient hepatic elastography in hepatitis C virus-infected hemodialysis patients.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


    November 2020
  37. LASHEN SA, Metawea MI, Shaaban A
    Direct antiviral drugs in the treatment of hepatitis C-infected rheumatoid arthritis Egyptian cohort: safety and clinical impact.
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002015.
    PubMed     Abstract available


  38. RIAL-CRESTELO D, Sepulveda MA, Gonzalez-Gasca FJ, Geijo-Martinez P, et al
    Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014-2018).
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002012.
    PubMed     Abstract available


  39. LITHY RM, Elbaz T, H Abdelmaksoud A, M Nabil M, et al
    Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000001972.
    PubMed     Abstract available


  40. RUIZ I, Fourati S, Ahmed-Belkacem A, Rodriguez C, et al
    Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000002003.
    PubMed     Abstract available


  41. TANG Y, Zhou H, Xiang Y, Cui F, et al
    The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000001978.
    PubMed     Abstract available


  42. KAYADIBI H, Yilmaz B, Ozgur Yeniova A, Koseoglu H, et al
    Development and evaluation of a novel noninvasive index for predicting significant fibrosis, advanced fibrosis, and cirrhosis in patients with chronic hepatitis B infection.
    Eur J Gastroenterol Hepatol. 2020 Nov 10. doi: 10.1097/MEG.0000000000001973.
    PubMed     Abstract available


    October 2020
  43. ATEF M, Zayed N, Salama R, Abdel Alem S, et al
    Is urinary beta2-microglobulin a reliable marker for assessment of renal tubular dysfunction in chronic hepatitis B patients receiving tenofovir therapy?
    Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001977.
    PubMed     Abstract available


  44. OMRAN M, Fouda M, Abdelwahab AO, Nabeel MM, et al
    P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001962.
    PubMed     Abstract available


  45. WANG X, Chen HZ, Liu WT, Liu M, et al
    The association of plasma high-density lipoprotein cholesterol levels and cirrhosis development in obese patients with chronic hepatitis B: a cohort study.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001965.
    PubMed     Abstract available


    September 2020
  46. STEIN K, Stoehr A, Klinker H, Teuber G, et al
    Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001923.
    PubMed     Abstract available


  47. AKSOY B, Baran M, Cagan Appak Y, Sag E, et al
    Efficiency of azathioprine monotherapy for maintenance treatment of autoimmune hepatitis in children.
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001930.
    PubMed     Abstract available


  48. TOVO CV, Ahlert M, Panke C, de Mattos AZ, et al
    Treatment of hepatitis B virus infection in chronic infection with HBeAg-positive adult patients (immunotolerant patients): a systematic review.
    Eur J Gastroenterol Hepatol. 2020 Sep 15. doi: 10.1097/MEG.0000000000001907.
    PubMed     Abstract available


  49. SEONG G, Sinn DH, Kang W, Gwak GY, et al
    Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase.
    Eur J Gastroenterol Hepatol. 2020 Sep 9. doi: 10.1097/MEG.0000000000001915.
    PubMed     Abstract available


    August 2020
  50. ABDO M, Rabiee A, Abdellatif Z, Abdel Alem S, et al
    Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001903.
    PubMed     Abstract available


  51. NUMAO H, Shimaya K, Kakuta A, Shibutani K, et al
    The utility of two-dimensional real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001887.
    PubMed     Abstract available


  52. KIM JH, Kang SH, Lee M, Choi HS, et al
    Individualized surveillance of chronic hepatitis B patients according to hepatocellular carcinoma risk based on PAGE-B scores.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001870.
    PubMed     Abstract available


  53. BEYAN C, Beyan E
    Mean platelet volume to platelet ratio may not be reliable to determine the severity of fibrosis in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2020;32:1067.
    PubMed    


  54. ELSADEK HM, Abdelbaser ES, Emara MH, Soliman HH, et al
    Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
    Eur J Gastroenterol Hepatol. 2020;32:1046-1053.
    PubMed     Abstract available


    July 2020
  55. OKAY G, Biberci Keskin E, Akkoyunlu Y, Bolukcu S, et al
    Evaluation of hepatitis B vaccine efficacy and factors affecting vaccine nonresponse in patients receiving anti-tumor necrosis factor agents.
    Eur J Gastroenterol Hepatol. 2020 Jul 14. doi: 10.1097/MEG.0000000000001849.
    PubMed     Abstract available


  56. DI LELLO FA, Blejer J, Alter A, Bartoli S, et al
    Seroprevalence of hepatitis E virus in Argentinean blood donors.
    Eur J Gastroenterol Hepatol. 2020 Jul 14. doi: 10.1097/MEG.0000000000001853.
    PubMed     Abstract available


  57. GUAN X, Xing F, Li Y
    Alcohol consumption increases the incidence of hepatocellular carcinoma in patients with hepatitis B cirrhosis but not in patients with hepatitis C cirrhosis.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001837.
    PubMed     Abstract available


  58. GARRIDO-ESTEPA M, Latasa P, Flores-Herrera J, Garcia Comas L, et al
    Hepatitis C and hepatitis C-related advanced liver disease hospitalisation trends before and after the Strategic Plan for Tackling Hepatitis C in the National Health System.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001841.
    PubMed     Abstract available


  59. CHEN SH, Huang CL, Chiang IP, Chang TC, et al
    Liver fibrosis regression correlates with downregulation in liver angiogenesis in chronic hepatitis C through viral eradication.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001833.
    PubMed     Abstract available


  60. MCPHAIL J, Sims OT, Guo Y, Wooten D, et al
    Fibrosis improvement in patients with HCV treated with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2020 Jul 3. doi: 10.1097/MEG.0000000000001821.
    PubMed     Abstract available


    June 2020
  61. YUKSEL M, Akturk H, Arikan C
    Immune monitoring of a child with autoimmune hepatitis and type 1 diabetes during COVID-19 infection.
    Eur J Gastroenterol Hepatol. 2020 Jun 16. doi: 10.1097/MEG.0000000000001804.
    PubMed     Abstract available


  62. ABDEL MOEZ AT, El Hawary YA, Al Balakosy AM
    Can successful treatment by direct-acting antivirals improve depression in chronic HCV patients?
    Eur J Gastroenterol Hepatol. 2020 Jun 16. doi: 10.1097/MEG.0000000000001790.
    PubMed     Abstract available


  63. DA BL, Lourdusamy V, Kushner T, Dieterich D, et al
    Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1097/MEG.0000000000001786.
    PubMed     Abstract available


  64. CHON HY, Seo YS, Lee JI, Kim BS, et al
    Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1097/MEG.0000000000001794.
    PubMed     Abstract available


    May 2020
  65. QIU LX, Liu YL, Lin W, Liu YR, et al
    Liver stiffness measurement is a potent predictor of histological fibrosis regression after hepatitis C virus clearance.
    Eur J Gastroenterol Hepatol. 2020 May 22. doi: 10.1097/MEG.0000000000001749.
    PubMed     Abstract available


  66. TSAI MC, Chang KC, Yen YH, Wu CK, et al
    Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites.
    Eur J Gastroenterol Hepatol. 2020 May 2. doi: 10.1097/MEG.0000000000001711.
    PubMed     Abstract available


  67. CHEUNGPASITPORN W, Thongprayoon C, Ungprasert P, Wijarnpreecha K, et al
    Hepatitis A hospitalizations among kidney transplant recipients in the United States: nationwide inpatient sample 2005-2014.
    Eur J Gastroenterol Hepatol. 2020;32:650-655.
    PubMed     Abstract available


  68. TANOGLU A
    Clinical utility of mean platelet volume and related scores for assessing the severity of hepatic fibrosis in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2020;32:664-665.
    PubMed    


    April 2020
  69. HINRICHSEN H, Stoehr A, Cornberg M, Klinker H, et al
    Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
    Eur J Gastroenterol Hepatol. 2020 Apr 25. doi: 10.1097/MEG.0000000000001759.
    PubMed     Abstract available


  70. CHEN D, Wen S, Wu Z, Gu Y, et al
    Association between effective hepatic blood flow and the severity and prognosis of hepatitis B virus-related acute on chronic liver failure.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001721.
    PubMed     Abstract available


  71. KUMADA T, Toyoda H, Tada T, Yasuda S, et al
    Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001733.
    PubMed     Abstract available


    March 2020
  72. YU HC, Tseng JC, Lu LY, Hu JC, et al
    Monitoring by viral load and quantitative hepatitis B surface antigen in patients with hepatitis B virus infection receiving immunosuppressive therapy.
    Eur J Gastroenterol Hepatol. 2020 Mar 20. doi: 10.1097/MEG.0000000000001707.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: